Li Rong, Wang Wen-Qing, Zhang Haifeng, Yang Xinchung, Fan Qian, Christopher Theodore A, Lopez Bernard L, Tao Ling, Goldstein Barry J, Gao Feng, Ma Xin L
Department of Physiology, The Fourth Military Medical University, Xian, China.
Am J Physiol Endocrinol Metab. 2007 Dec;293(6):E1703-8. doi: 10.1152/ajpendo.00462.2007. Epub 2007 Sep 25.
Plasma adiponectin level is significantly reduced in patients with metabolic syndrome, and vascular dysfunction is an important pathological event in these patients. However, whether adiponectin may protect endothelial cells and attenuate endothelial dysfunction caused by metabolic disorders remains largely unknown. Adult rats were fed with a regular or a high-fat diet for 14 wk. The aorta was isolated, and vascular segments were incubated with vehicle or the globular domain of adiponectin (gAd; 2 mug/ml) for 4 h. The effect of gAd on endothelial function, nitric oxide (NO) and superoxide production, nitrotyrosine formation, gp91(phox) expression, and endothelial nitric oxide synthase (eNOS)/inducible NOS (iNOS) activity/expression was determined. Severe endothelial dysfunction (maximal vasorelaxation in response to ACh: 70.3 +/- 3.3 vs. 95.2 +/- 2.5% in control, P < 0.01) was observed in hyperlipidemic aortic segments, and treatment with gAd significantly improved endothelial function (P < 0.01). Paradoxically, total NO production was significantly increased in hyperlipidemic vessels, and treatment with gAd slightly reduced, rather than increased, total NO production in these vessels. Treatment with gAd reduced (-78%, P < 0.01) superoxide production and peroxynitrite formation in hyperlipidemic vascular segments. Moreover, a moderate attenuation (-30%, P < 0.05) in gp91(phox) and iNOS overexpression in hyperlipidemic vessels was observed after gAd incubation. Treatment with gAd had no effect on eNOS expression but significantly increased eNOS phosphorylation (P < 0.01). Most noticeably, treatment with gAd significantly enhanced eNOS (+83%) but reduced iNOS (-70%, P < 0.01) activity in hyperlipidemic vessels. Collectively, these results demonstrated that adiponectin protects the endothelium against hyperlipidemic injury by multiple mechanisms, including promoting eNOS activity, inhibiting iNOS activity, preserving bioactive NO, and attenuating oxidative/nitrative stress.
代谢综合征患者的血浆脂联素水平显著降低,血管功能障碍是这些患者的一个重要病理事件。然而,脂联素是否可以保护内皮细胞并减轻代谢紊乱引起的内皮功能障碍,在很大程度上仍然未知。将成年大鼠喂以常规饮食或高脂饮食14周。分离主动脉,将血管段与载体或脂联素球状结构域(gAd;2μg/ml)孵育4小时。测定gAd对内皮功能、一氧化氮(NO)和超氧化物生成、硝基酪氨酸形成、gp91(phox)表达以及内皮型一氧化氮合酶(eNOS)/诱导型一氧化氮合酶(iNOS)活性/表达的影响。在高脂血症主动脉段观察到严重的内皮功能障碍(对乙酰胆碱的最大血管舒张:70.3±3.3% vs. 对照组的95.2±2.5%,P<0.01),用gAd治疗可显著改善内皮功能(P<0.01)。矛盾的是,高脂血症血管中的总NO生成显著增加,而用gAd治疗会轻微降低而不是增加这些血管中的总NO生成。用gAd治疗可降低高脂血症血管段中的超氧化物生成和过氧亚硝酸盐形成(-78%,P<0.0)。此外,在gAd孵育后,观察到高脂血症血管中gp91(phox)和iNOS过表达有中度减弱(-30%,P<0.05)。用gAd治疗对eNOS表达没有影响,但显著增加了eNOS磷酸化(P<0.01)。最值得注意的是,用gAd治疗可显著增强高脂血症血管中的eNOS(+83%)但降低iNOS(-70%,P<)活性。总的来说,这些结果表明脂联素通过多种机制保护内皮细胞免受高脂血症损伤,包括促进eNOS活性、抑制iNOS活性、保留生物活性NO以及减轻氧化/硝化应激。